Advertisement
UK markets close in 1 hour 37 minutes

  • FTSE 100

    8,370.46
    +16.41 (+0.20%)
     

  • FTSE 250

    20,541.15
    +49.16 (+0.24%)
     

  • AIM

    782.76
    +2.93 (+0.38%)
     

  • GBP/EUR

    1.1611
    -0.0011 (-0.10%)
     

  • GBP/USD

    1.2499
    +0.0002 (+0.02%)
     

  • Bitcoin GBP

    48,929.96
    -743.01 (-1.50%)
     

  • CMC Crypto 200

    1,321.69
    +21.60 (+1.66%)
     

  • S&P 500

    5,185.47
    -2.20 (-0.04%)
     

  • DOW

    39,104.97
    +48.58 (+0.12%)
     

  • CRUDE OIL

    79.15
    +0.16 (+0.20%)
     

  • GOLD FUTURES

    2,326.40
    +4.10 (+0.18%)
     

  • NIKKEI 225

    38,073.98
    -128.39 (-0.34%)
     

  • HANG SENG

    18,537.81
    +223.95 (+1.22%)
     

  • DAX

    18,668.01
    +169.63 (+0.92%)
     

  • CAC 40

    8,166.20
    +34.79 (+0.43%)
     
Money:

Best UK mortgage deals of the week

As Bank of England holds interest rates, here's what high street banks are offering home buyers

Cerus Corporation (CERS) Looks Good: Stock Adds 8.2% in Session

Zacks Equity Research
Updated

Cerus Corporation CERS  was a big mover last session, as the company saw its shares rise over 8% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This stock, which remained volatile and traded within the range of $2.5–$2.9 in the past one-month time frame, witnessed a sharp increase yesterday.

The price appreciation took place on the back of the news that the U.S. Food and Drug Administration approved the Rhode Island Blood Center's Biologics License Application (BLA) for the interstate distribution of platelets that have been pathogen-reduced with the Intercept Blood System.

The company has seen no estimate revisions over the past one month, and the Zacks Consensus Estimate for the current quarter has also remained unchanged. The recent price action is encouraging though, so make sure to keep a close watch on this firm in the near future.

Cerus currently has a Zacks Rank #4 (Sell) while its Earnings ESP is 0.00%.

Cerus Corporation Price and Consensus

Cerus Corporation Price and Consensus | Cerus Corporation Quote

ADVERTISEMENT

A better-ranked stock in the    Medical - Products industry is Essilor International SA ESLOY, which currently carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Is CERS going up? Or down? Predict to see what others think: Up or Down

5 Trades Could Profit ""Big-League"" from Trump Policies

If the stocks above spark your interest, wait until you look into companies primed to make substantial gains from Washington's changing course.

Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals, tariffs, lower taxes, higher interest rates, and spending surges in defense and infrastructure.

See these buy recommendations now >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Essilor International SA (ESLOY) : Free Stock Analysis Report
 
Cerus Corporation (CERS) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research